

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
In this collaboration, Applied BioMath is developing a model of SpringWorks' investigational oral selective small molecule gamma secretase inhibitor, nirogacestat (PF-03084014), in combination with an agent that targets B-cell maturation antigen for multiple myeloma.
Lead Product(s): Nirogacestat,Undisclosed
Therapeutic Area: Oncology Product Name: PF-03084014
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SpringWorks Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2022
Details:
Under the agreement, Celsius Therapeutics will collaborate for the development of a systems pharmacology model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Celsius Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 04, 2022
Details:
Applied BioMath will develop a systems pharmacology model for CLN-049, a novel FLT3XCD3 bispecific antibody for Acute Myeloid Leukemia, being developed by Cullinan Florentine, a Cullinan Oncology company.
Lead Product(s): CLN-049
Therapeutic Area: Oncology Product Name: CLN-049
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cullinan Oncology, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 29, 2020
Details:
Applied BioMath will develop a systems pharmacology model to mechanistically evaluate the pharmacokinetics and pharmacodynamics of OncoMyx's MYXV platform and therapeutic programs.
Lead Product(s): Myxoma virus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: OncoMyx Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 14, 2020